Table 1.
Patient characteristics.
| All | Training cohort | Validation cohort | p value∗ | |
|---|---|---|---|---|
| N (%) | 152 (100) | 102 (100.0) | 50 (100.0) | |
| Age (years); median (IQR) | 48 (32–63) | 48 (33–61) | 51 (30–66) | >0.9 |
| Sex (males); n (%) | 102 (67) | 64 (63) | 38 (76) | 0.5 |
| BMI (kg/m2); median (IQR) | 26.6 (23.2–30.0) | 27.1 (23.8–31.0) | 25.6 (22.3–28.4) | 0.4 |
| Ethnicity; n (%) | >0.9 | |||
| Caucasian | 122 (84) | 85 (84) | 37 (82) | |
| African-American | 21 (14) | 14 (14) | 7 (16) | |
| Other | 3 (2.1) | 2 (2) | 1 (2.2) | |
| Alcohol abuse; n (%) | 16 (11) | 13 (13) | 3 (6.2) | 0.7 |
| Cholecystectomy at baseline; n (%) | 13 (8.6) | 9 (8.8) | 4 (8.0) | >0.9 |
| Type of IBD; n (%) | >0.9 | |||
| Ulcerative colitis | 85 (76) | 62 (77) | 23 (74) | |
| Crohn’s disease | 26 (23) | 18 (22) | 8 (26) | |
| Indeterminate colitis | 1 (0.9) | 1 (1.2) | 0 (0.0) | |
| UDCA class; n (%) | >0.9 | |||
| Non-user | 63 (43) | 40 (41) | 23 (46) | |
| Regular dose UDCA | 76 (51) | 52 (53) | 24 (48) | |
| High dose UDCA | 9 (6.1) | 6 (6.1) | 3 (6.0) | |
Data are presented as mean (SD) or median (IQR) for continuous variables, and as numbers and percentages (%) for categorical data.
BMI, body mass index; IBD, inflammatory bowel disease; IQR, interquartile range; UDCA, ursodeoxycholic acid.
∗
Bonferroni corrected p value.